IdentifAI Genetics Information

Identifai Genetics Limited (ASX:ID1) is developing prenatal genetic screening technology that combines genomic analysis, artificial intelligence and machine learning to assess selected inherited conditions affecting the fetus. Its first product, Windrose™, is designed around a single maternal blood sample, without requiring a paternal sample in the intended screening workflow. The Company is focused on commercialising its technology in the United States first, with the aim of providing information earlier in pregnancy to support clinician-led investigation and care planning. Screening findings may require confirmatory diagnostic testing. Identifai Genetics is part of the Shizim VS portfolio, an Israeli innovation center led by Yossi Bornstein the Co-founder, who serves as both CEO of Shizim and Chairman of Identifai Genetics.